Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention...
-
Upload
conrad-randall -
Category
Documents
-
view
216 -
download
2
Transcript of Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention...
![Page 1: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/1.jpg)
Cyclosporin Nephrotoxicity
![Page 2: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/2.jpg)
Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients and autoimmune diseases.
![Page 3: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/3.jpg)
How cyclosporin nephrotoxicity is manifested
Long term usage of Cyclosporin generally may results in Cyclosporin Nephrotoxicity
Short term usage at high dosages can also cause Cyclosporin Nephrotoxicity
![Page 4: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/4.jpg)
Characterised by: Renal dysfunction, Reduced GFR , Reduced renal blood flow, Rise in serum creatinine, Decrease in renal clearance, Rise in RAS, Arteriolopathy of afferent ateriole, Vascular dysfunction and Elevated BUN.
![Page 5: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/5.jpg)
Monitoring procedures: Biochemical monitoring: Radioimmunoassay fluorescent polarization Immunoassays homogeneous immunoassays high-performance liquid chromatography–
mass spectrometry
![Page 6: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/6.jpg)
Clinical Monitoring: Renal function tests Liver function tests BUN Bilirubin Trough cyclosporin blood concentration Renal biopsy Blood pressure FBC
![Page 7: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/7.jpg)
Explain whether it is possible to distinguish between the adverse renal effects of cyclosporin and graft rejection.
![Page 8: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/8.jpg)
Similarly… Increase in Creatinine Serum Decrease in GFR Decrease in Creatinine Clearance Increase in BUN
![Page 9: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/9.jpg)
However…Renal Transplant Rejection Cyclosporin Nephrotoxicity
Acute onset Variable onset
Fever No fever
Rapid rise in Creatinine Gradual rise in Creatinine
No change in serum Urate level
Urate Retention
No change in serum magnesium level
Reduced serum magnesium
Cyclosporin A trough level <150 ng/ml
Cyclosporin A level > 400 ng/ml
![Page 10: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/10.jpg)
1/ Cyclosporine-Sparing EffectThe introduction of one or more
agents with Cyclosporine in order to achieve the therapeutic drug concentration at lower doses.
![Page 11: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/11.jpg)
2/ Benefits Associated Vast reduction in cost (Cyclosporine is very expensive) Reduced side effects (toxicity is a major issue to contend with)
![Page 12: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/12.jpg)
3/ Agents typically used
Azole antifungals: Fluconazole, Ketoconazole and Itraconazole
Ca2+ channel blockers: Verapamil, Diltiazem and Nicardipine
Other immunosuppressants such as Siromilus or Mycophenolate Mofetil
Macrolide antibiotics such as erythromycin (rarely used)
![Page 13: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/13.jpg)
4/ Azole Antifungals MOA
Include Ketoconazole, Fluconazole and Itraconazole Have the ability to increase the blood cyclosporine
concentration by two means: Firstly via inhibition of the CYP3A4 enzyme,
responsible for the metabolism of cyclosporine, and Decreasing the clearance of cyclosporine from the
body Results in a 70 to 85% reduction in cyclosporine
dose required
![Page 14: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/14.jpg)
5/ Ca2+ Channel Blockers MOAInclude Diltiazem, Verapamil and Nicardipine Similar MOA to azoles but have minimal
ability to decrease the clearance of cyclosporine in comparison
As a result the effectiveness of these agents is smaller, with a 30-50% reduction in cyclosporine dose achieved.
![Page 15: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/15.jpg)
6/ Other Immunosuppressants Include Siromilus and Mycophenolate
Mofetil Work synergistically with cyclosporine,
inhibiting lymphocyte activation and proliferation.
Effect is very powerful and the immune system becomes quickly weakened.
![Page 16: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/16.jpg)
7/ Most effective agents
Ketoconazole and Diltiazem appear to be the best candidates when considering the two mot important issues; financial pressures and the patients' well being.
![Page 17: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/17.jpg)
Mathematical Calculations of Renal Function. Why these approaches have been
developed?
![Page 18: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/18.jpg)
Ideal marker to measure CL Physically inert Filtered freely at the glomerulus Neither secreted, reabsorbed, synthesised,
nor metabolised by the kidney Stable production rate Cl depends only on glomerular filtration
![Page 19: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/19.jpg)
Inulin (sinsitrin) Exogenous marker of GFR Precise measurement Method:
Intravenous infusion Urine collections Problems:
$$, time, not feasible in clinical setting.
![Page 20: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/20.jpg)
Radioactive markers Exogenous markers 125I- iothalamate 99mTc- DTPA Problems:
Not readily available Time consuming
![Page 21: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/21.jpg)
Creatinine By-product of muscle Predominately eliminated by glomerular
filtration Inexpensive Problems:
Poor sensitivity, specificity.
![Page 22: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/22.jpg)
Method 24-hr urine collection: To determine creatinine clearance
CrCl (mL/min): Ucr * Vurine
Scr * T
Serum creatinine concentration
![Page 23: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/23.jpg)
24 hr urine collectionProblems:
Incomplete urine collections Serum creatinine concentrations obtained
at incorrect times Collection time errors can produce
erroneous measured creatinine clearance values.
![Page 24: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/24.jpg)
Quick Methods to estimate CrCl Equations postulated by clinicians to
predict GFR. From serum creatinine values and patient
characteristics in various populations.
![Page 25: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/25.jpg)
Cockcroft and Gault equationClcr(male) = BW *(140-age) / 72*Crserum
Clcr(female) = above equation*0.85
BW (body weight) - Kg
Age - years
Crserum - mg/dL
Note: formula different for men and women because of gender dependent differences in muscle mass.
![Page 26: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/26.jpg)
Cockcroft and Gault equationAssumptions: Stable renal function Actual weight within 30% of IBW.
(Normal muscle mass). Crserum< 4.5mg/dL
Limitations: 18 yrs and older.
![Page 27: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/27.jpg)
Jelliffe multistep equationEstimate urinary Cr excretion rate
E(male) = LBW(29.3 – (0.203 * age))
E(female) = LBW(25.1 – (0.175 * age))Correct E for non reanl Cr excretion in chronic renal failure
E(corrected) = E(1.035 – (0.0337 * Crserum(avg))Correct E for rising serum Cr
E = E – (4 * LBW * (Crserum1 – Crserum2))/TimeCalc normalised CrCl
CrCl/1.73m2 = (E * 0.12) / (Crserum * BSA)
![Page 28: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/28.jpg)
Jelliffe multistep equationAsumptions: Avg. BSA for a 70kg male is 1.73m2
Clcr value obtained must then be multiplied by BSA/1.73 to obtain the patients’ Clcr in absolute terms (ie mL/min).
Limitations: Muscle mass must be in the avg range.
![Page 29: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/29.jpg)
Swartz CrCl equtionClcr = (k * Ht) / Crserum
Clcr in mL/min/1.73m2
Ht- height in cm
Crserum- mg/mL
K = 0.45 if age < 1 year
K = 0.55 if age 1-12 years.
BSA normalised to 1.73m2
![Page 30: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/30.jpg)
Salazar and Corcoran equationClcr(male) = (137-age)*((0.2858*Wt) + (12.1*Ht2))
51*Crserum
Clcr(female) = (146-age)*((0.287*Wt) + (9.74*Ht2))
60 *Crserum
Ht:height in metres
Wt: weight in kg
Age in years.
A specific measure for obese people
![Page 31: Cyclosporin Nephrotoxicity Some of the indications for the use of cyclosporin include the prevention of graft rejection in renal transplant recipients.](https://reader036.fdocuments.us/reader036/viewer/2022062721/56649f1d5503460f94c347eb/html5/thumbnails/31.jpg)
References: Pathology The Chinese University of Hong Kong, Chemical Pathology in Organ Transplantation , Department of
Chemical, 2000 http://www.transplantbuddies.org/library/tdm.html. Visited 23/3/04 . Johnston, Atholl * . Chusney, Gary + . Schutz, Ekkehard ++ . Oellerich, Michael ++ . Lee, Terry D. +. Holt, David
W. +. Monitoring Cyclosporin in Blood: Between-Assay Differences at Trough and 2 Hours Post-dose (C2). Therapeutic Drug Monitoring. 25(2):167-173, April 2003.
Morris, Raymond G.. Lam, Ada K.. Cyclosporin Monitoring in Australasia: Survey of Laboratory Practices in 2000. Therapeutic Drug Monitoring. 24(4):471-478, August 2002.